account_id none on file
legal_name Immix Biopharma, Inc.
ticker IMMX
cik 1873835
domain immixbio.com
linkedin_company_url https://www.linkedin.com/company/immix-biopharma/
entry_point_account_id none on file
name Immix Biopharma Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 4 executives 0 family 0
why_nownone on file
callsnone on file
filings
compensation, of $1,681,376 due to hiring of additional employees, and increased other general expenses of $332,210. Research and Development Expense Research and development expense was $5,333,172 for the three months ended June 30, 2026, compared to $3,972,458 for the three months ended June 30, 2025.
filing / Aug 7, 2026 / receipt
compensation, of $2,194,338 due to hiring of additional employees, and increased other general expenses of $765,097. Research and Development Expense Research and development expense was $11,3313,649 for the six months ended June 30, 2026, compared to $5,947,532 for the six months ended June 30, 2025.
filing / Aug 7, 2026 / receipt
which Gabriel Morris, the Company’s Chief Financial Officer and a member of the Board, is sole member, which was amended effective
filing / May 7, 2026 / receipt
related to the Company’s efforts to raise capital, increased compensation of $607,006 due to hiring of additional employees, and
filing / May 7, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-06 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug immix-biopharma-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$